CSL312
Sponsors
CSL Behring
Conditions
Healthy ParticipantsHealthy VolunteersHereditary AngioedemaHereditary Angioedema (HAE)PICC-associated Thrombosis
Phase 1
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line
WithdrawnNCT04281524
Start: 2020-03-31End: 2021-10-31Updated: 2020-03-25
A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults
CompletedNCT04580654
Start: 2020-10-29End: 2021-05-07Updated: 2022-10-04
A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects
CompletedNCT05306275
Start: 2022-04-04End: 2022-09-27Updated: 2022-10-06
Phase 3
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
CompletedNCT04656418
Start: 2021-01-27End: 2022-06-07Updated: 2023-06-29
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
CompletedNCT04739059
Start: 2021-03-29End: 2025-11-21Updated: 2026-06-02
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
CompletedNCT05819775
Start: 2023-05-30End: 2025-11-19Updated: 2026-06-02